In vivo programming of dual-targeted CAR-T cells facilitates vascular disruption and T-cell infiltration in solid tumors
T-cell therapies for solid tumors are restricted by abnormal tumor vasculature, which creates structural and immunological barriers to infiltration. Here we report a programmable mRNA lipid nanoparticle (LNP) platform that orchestrates a division-of-labor immune response in vivo. By modulating the LNP nano-bio interface through 10% 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (DOPS) doping and indirect IgG-based anti-CD5 tethering, we achieve selective and efficient transfection of endogenous splenic T cells. This platform simultaneously generates two complementary chimeric antigen receptor (CAR)-T populations: a vascular endothelial growth factor receptor 2 (VEGFR2)-directed subset that transiently remodels the tumor endothelium, and a tumor-antigen-directed subset that executes cytotoxic clearance. Mechanistic analyses reveal that focal endothelial disruption creates a permissive window for the infiltration, expansion, and activation of tumor-directed CAR-T cells. In refractory melanoma and colorectal carcinoma models in female mice, this dual-programming strategy achieves superior tumor control and drives tumor regression while reducing systemic toxicity. By bypassing ex vivo manufacturing, this approach provides a scalable and host-directed strategy to breach infiltrative barriers in solid-tumor immunotherapy.
Authors
- Shijing Wang (ORCID: https://orcid.org/0000-0001-9636-2310)
- Zhong Sheng Sun (ORCID: https://orcid.org/0000-0002-7640-5026)
- 程晋
- Bozhao Li (ORCID: https://orcid.org/0000-0001-7566-5638)
- Guangjun Nie (ORCID: https://orcid.org/0000-0001-5040-9793)
- Suying Wu (ORCID: https://orcid.org/0009-0008-3790-9134)
- Bo Zhu (ORCID: https://orcid.org/0000-0003-0224-8512)
- Fei Wu (ORCID: https://orcid.org/0009-0009-1879-2169)
- Tianjiao Chu (ORCID: https://orcid.org/0009-0007-0316-1810)
- Zefang Lu (ORCID: https://orcid.org/0009-0002-7538-9922)
- Suping Li (ORCID: https://orcid.org/0000-0002-0294-8861)
- Mengyao Li (ORCID: https://orcid.org/0000-0001-7298-625X)
- Jinna Ren
- Lifang Guo
- Junsong Huang
- Zhouliang Wu
- Yuming Fu
Institutions
- Army Medical University (CN)
- Capital Medical University (CN)
- Chinese Academy of Sciences (CN)
- Harbin Institute of Technology (CN)
- Beijing Chao-Yang Hospital, Capital Medical University (CN)
- Chinese PLA General Hospital (CN)
- Xinqiao Hospital (CN)
- Second Hospital of Tianjin Medical University (CN)
- National Center for Nanoscience and Technology (CN)
- Chinese People's Liberation Army (CN)
- University of Chinese Academy of Sciences (CN)
- Institute of Zoology (CN)
- Tianjin Medical University (CN)
- Beihang University (CN)
- Ministry of Industry and Information Technology (CN)
Publication Details
- Journal
- Nature Communications
- Published
- 2026-11-19
- DOI
- https://doi.org/10.1038/s41467-026-79342-7
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00